HLB Therapeutics Co.,Ltd.
115450
Rank in Stocks
#18716
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Share Price
$1.88
Market Cap
$177.26M
Change (1 day)
-0.73%
Change (1 year)
-6.17%
Country
KR
Trade HLB Therapeutics Co.,Ltd. (115450)
Category
Healthcare
EPS for HLB Therapeutics Co.,Ltd. (115450)
EPS as of 2026 TTM: 0
According to HLB Therapeutics Co.,Ltd. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for HLB Therapeutics Co.,Ltd. from 2026 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
